| Primary |
| Antiviral Prophylaxis |
17.7% |
| Prophylaxis Against Transplant Rejection |
16.0% |
| Cytomegalovirus Infection |
11.4% |
| Product Used For Unknown Indication |
7.8% |
| Drug Use For Unknown Indication |
6.2% |
| Immunosuppression |
4.7% |
| Prophylaxis |
4.3% |
| Hypertension |
4.1% |
| Antibiotic Prophylaxis |
3.8% |
| Antifungal Prophylaxis |
3.8% |
| Infection Prophylaxis |
2.6% |
| Procedural Pain |
2.6% |
| Immunosuppressant Drug Therapy |
2.2% |
| Diabetes Mellitus |
2.1% |
| Prophylaxis Against Gastrointestinal Ulcer |
2.1% |
| Thrombosis Prophylaxis |
2.1% |
| Idiopathic Thrombocytopenic Purpura |
1.9% |
| Transplant Rejection |
1.8% |
| Gastrooesophageal Reflux Prophylaxis |
1.6% |
| Colitis Ulcerative |
1.2% |
|
| Drug Resistance |
19.1% |
| Drug Ineffective |
14.5% |
| Cytomegalovirus Infection |
5.5% |
| Thrombocytopenia |
5.5% |
| Bone Marrow Failure |
4.5% |
| Death |
4.5% |
| Interstitial Lung Disease |
4.5% |
| Neutropenia |
4.5% |
| Neutrophil Pelger-huet Anomaly Present |
4.5% |
| Transplant Rejection |
4.5% |
| Pneumonia Cytomegaloviral |
3.6% |
| Renal Failure Acute |
3.6% |
| Sepsis |
3.6% |
| Herpes Zoster |
2.7% |
| Pancytopenia |
2.7% |
| Psychotic Disorder |
2.7% |
| Pulmonary Embolism |
2.7% |
| White Blood Cell Count Decreased |
2.7% |
| Coma |
1.8% |
| Cytomegalovirus Gastroenteritis |
1.8% |
|
| Secondary |
| Drug Use For Unknown Indication |
22.0% |
| Hiv Infection |
16.9% |
| Cytomegalovirus Infection |
9.9% |
| Product Used For Unknown Indication |
7.5% |
| Prophylaxis |
7.3% |
| Immunosuppression |
6.2% |
| Prophylaxis Against Transplant Rejection |
5.0% |
| Immunosuppressant Drug Therapy |
3.7% |
| Antiviral Prophylaxis |
3.3% |
| Mycobacterium Avium Complex Infection |
2.6% |
| Antifungal Prophylaxis |
2.4% |
| Colitis Ulcerative |
1.8% |
| Gastric Ulcer |
1.7% |
| Castleman's Disease |
1.6% |
| Cytomegalovirus Chorioretinitis |
1.6% |
| Oesophageal Ulcer |
1.5% |
| Antibiotic Prophylaxis |
1.4% |
| Infection Prophylaxis |
1.4% |
| Renal Transplant |
1.2% |
| Hypertension |
1.0% |
|
| White Blood Cell Count Decreased |
12.9% |
| Cytomegalovirus Infection |
9.4% |
| Vomiting |
9.1% |
| Thrombocytopenia |
8.0% |
| Drug Resistance |
7.0% |
| Transplant Rejection |
6.3% |
| Neutrophil Pelger-huet Anomaly Present |
4.9% |
| Renal Failure Acute |
4.9% |
| Pancytopenia |
4.5% |
| Hepatic Enzyme Increased |
4.2% |
| Thrombotic Microangiopathy |
4.2% |
| Neutropenia |
3.8% |
| Sepsis |
3.8% |
| Renal Failure |
3.1% |
| Renal Impairment |
2.8% |
| Liver Disorder |
2.4% |
| Cytomegalovirus Chorioretinitis |
2.1% |
| Encephalitis Cytomegalovirus |
2.1% |
| Pneumonia Cytomegaloviral |
2.1% |
| Retinitis |
2.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
12.8% |
| Prophylaxis |
12.4% |
| Hiv Infection |
8.7% |
| Infection Prophylaxis |
7.5% |
| Prophylaxis Against Graft Versus Host Disease |
7.2% |
| Drug Use For Unknown Indication |
6.6% |
| Bone Marrow Conditioning Regimen |
6.2% |
| Antifungal Prophylaxis |
4.9% |
| Antiviral Prophylaxis |
4.6% |
| Cytomegalovirus Infection |
3.4% |
| Prophylaxis Against Transplant Rejection |
3.3% |
| Antibiotic Prophylaxis |
3.1% |
| Renal Transplant |
2.9% |
| Immunosuppression |
2.8% |
| Acute Myeloid Leukaemia |
2.6% |
| Lung Transplant |
2.5% |
| Premedication |
2.4% |
| Graft Versus Host Disease |
2.3% |
| Acute Lymphocytic Leukaemia |
1.9% |
| Hypertension |
1.8% |
|
| White Blood Cell Count Decreased |
10.8% |
| Sepsis |
8.0% |
| Pyrexia |
7.1% |
| Weight Decreased |
6.5% |
| Pneumonia |
6.1% |
| Respiratory Failure |
6.1% |
| Cytomegalovirus Infection |
5.8% |
| Vomiting |
5.6% |
| Thrombotic Microangiopathy |
5.4% |
| Death |
4.5% |
| Renal Failure |
4.5% |
| Septic Shock |
4.5% |
| Renal Failure Acute |
4.3% |
| Transplant Rejection |
3.7% |
| Multi-organ Failure |
3.5% |
| White Blood Cell Count Increased |
3.2% |
| Pneumonia Cytomegaloviral |
3.0% |
| Thrombocytopenia |
2.8% |
| Drug Ineffective |
2.6% |
| Stomach Mass |
2.4% |
|
| Interacting |
| Cytomegalovirus Gastroenteritis |
50.0% |
| Herpes Zoster |
50.0% |
|
|
